HEALTHCARE & PHARMACEUTICALS MARKET RESEARCH
Category: Auto-immune diseases
-
Adalimumab’s competition and immense market Growth Potential of 5.1%
Adalimumab is a medicine that belongs to the class of biologic DMARDs (disease-modifying antirheumatic medications). Humira is a common brand name used in marketing.
-
HERE’S WHAT WE KNOW ABOUT COVID-19 AND AUTOIMMUNITY
Before we get into understanding the possible links between autoimmunity and COVID-19, it is imperative that we understand what autoantibodies are and how they affect our body. These self-attacking antibodies…
-
WHY IS OUR IMMUNE SYSTEM ATTACKING US?
When a foreign substance enters our body, it identifies the danger and our immune system then produces antibodies in response to the antigen that may be present on the surface…
Follow Us
Recent Posts
-
Bedaquiline Role in Treating Tuberculosis having a hefty $1.38 billion dollar market
-
Adalimumab’s competition and immense market Growth Potential of 5.1%
-
Semaglutide’s massive influence on the Diabetes Pharmaceutical Market and 6 competitors
-
FDA approved Leqembi to have $12.9 billion sales
-
Assistive Technology Market; a $82B Growth Story
Tags
Autoimmunity cancer cancer research cancer therapy CDSCO covid-19 covid in children Diabetes drug Elderly Health FDA healthcare immune response Kerala mutations Nipah virus pandemic PCOS pharma Pharmaceutical market pharma sector protein-based vaccines sars-cov-2 therapy third wave Treatment vaccine variants WHO zydus cadila